A reformulated liposome drug delivery system produced local anesthesia lasting two to three weeks in rats, against four to eight hours for a commercial formulation, according to results published in Nature Biomedical Engineering. The paper, "Ultra-slow release of hydrophilic drugs via multilamellar–multivesicular liposomes formed by unsaturated phospholipids," comes from the laboratory of Daniel Kohane, MD, PhD, director of the Laboratory for Biomaterials and Drug Delivery at Boston Children's Hospital.

The finding matters well beyond anesthesiology. Sustained release of hydrophilic molecules is a persistent formulation problem: extend the release window and you cut dosing frequency for repeat injectables, or hold drug levels effective at a specific site for weeks instead of hours. Most local anesthetics in clinical use today last eight to 12 hours, or a day at most.

What did the researchers actually overturn?

The work challenges a standing assumption in liposome design. The field held that drugs leak fastest from liposomes built with more "fluid" lipids — membranes whose tails carry many double chemical bonds and therefore cannot pack tightly. Yuan Wang, PhD, a research engineer in Kohane's lab, showed the opposite holds for hydrophilic drugs, the compounds that dissolve or mix readily in water.

The mechanism is structural. Using imaging, the team demonstrated that liposomes with many double bonds form multiple internal compartments, while those without adopt a simple single-sphere geometry. Each compartment adds a lipid barrier a dissolved drug must cross before escaping.

"The more fluid membranes in liposomes with many double bonds may be easier to cross, but the greater number of barriers slow down the drug's release," Wang said. "The more fluid liposomes with more double bonds may form concentric spheres that are like onions with many layers or could even potentially be even spheres within spheres."

For formulation groups, the practical takeaway is that lipid unsaturation — previously tuned to accelerate release — can instead gate release kinetics for water-soluble cargo, with compartment count as the controlling variable.

How strong is the evidence?

The in vivo result is a proof-of-principle in rats, not a clinical trial. The team loaded its multilamellar liposomes with tetrodotoxin, the potent neurotoxin found in pufferfish and blue-ringed octopuses that acts as a powerful numbing agent. Injected near a leg nerve in rats, the formulation produced very prolonged local anesthesia with no observed toxicity at the injection site or systemically.

That safety observation carries weight because it indicates a workable release-and-clearance balance: drug exits the carrier slowly enough for the body to clear it, yet fast enough to maintain anesthetic levels. Researchers should note the caveats. The dataset is rodent; the authors themselves point out that nerve blocks in humans tend to run longer than in rats, which they argue would extend — not shrink — the effective window relative to the two-to-three-week rat figure. And tetrodotoxin is not commercially approved for patients; it remains a candidate therapeutic.

The measured claims and the projections should be kept separate. Measured: multilamellar structure, two-to-three-week rat nerve block, absence of local and systemic toxicity in those animals. Projected: translation to human perioperative pain, opioid-sparing use, and extension to chronic pain.

Where could this fit a portfolio?

Kohane frames two application tracks. "This extended-release combination could be used for longer term perioperative pain instead of opioids, and we are starting to consider using these potentially for chronic pain, as well," he said, adding: "These liposomes can also provide slow release of a wide range of hydrophilic molecules."

That second claim is the broader one for R&D planners. If the unsaturated-phospholipid architecture generalizes across hydrophilic cargo — a claim that will need its own case-by-case validation for each payload — the platform could serve as a delivery vehicle beyond anesthetics, for any injectable where dosing frequency drives compliance, cost, or exposure risk.

For now, the milestone is mechanistic: a design rule linking lipid double-bond density, multivesicular structure, and release rate, demonstrated in vivo with a two-to-three-week nerve block. The next questions — scale-up behavior of multilamellar batches, payload generality, and whether the tetrodotoxin safety profile holds in larger animals — will determine whether the platform moves beyond the Kohane lab's proof of principle.